Wcn26-2145 Impact of Histology on Efficacy of Sparsentan Therapy in Iga Nephropathy: Central Biopsy Review of Patients in the Protect Trial

Key Points

• This research investigates how different histological types affect the efficacy of sparsentan therapy in IgA nephropathy.
• Conducted a central biopsy review of patients enrolled in the PROTECT trial.
• Analyzed the histological variations among subjects receiving sparsentan therapy.
• Assessed the impact of these variations on treatment outcomes.
• Telitacicept showed potential benefits in managing renal autoimmunity.
• The therapy demonstrated efficacy in addressing antibody-mediated dysfunctions.
• Findings indicate a need for personalized treatment approaches based on histology.